The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II Bridge SBIR entitled “Riluzole Prodrugs for Melanoma and ALS”
Doylestown, PA. September 3, 2018 – FCCDC is pleased to announce that it has been awarded a Phase II Bridge SBIR entitled “Riluzole Prodrugs for Melanoma and ALS” (2R44CA156781-04A1) to study troriluzole (formerly trigriluzole) for the treatment of solid tumors in combination with anti-PD1 checkpoint inhibitors.